Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Volume 4
Erscheinungsjahr 2018
ISBN: 978-0-12-816435-8
Verlag: Elsevier Science

Buch, Englisch, 292 Seiten, Format (B × H): 243 mm x 200 mm, Gewicht: 770 g

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials.

Zielgruppe

<p>cancer researchers; oncologists; pharmacists; graduate students on cancer studies</p>

Autoren/Hrsg.

Bonavida, Benjamin

Weitere Mitwirkende

Bonavida, Benjamin

Chen, Zhe-Sheng (Jason)

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Chemotherapie

Inhaltsverzeichnis

1. EGFR and HER2 inhibitors as sensitizing agents for cancer chemotherapy2. BCR-ABL inhibitors as sensitizing agents for cancer chemotherapy3. VEGFR inhibitors as sensitizing agents for cancer chemotherapy4. ALK inhibitors as sensitizing agents for cancer chemotherapy5. JAK2 inhibitors as sensitizing agents for cancer chemotherapy6. FLT3 inhibitors as sensitizing agents for cancer chemotherapy7. BRAF inhibitors as sensitizing agents for cancer chemotherapy8. Bruton kinase inhibitors as sensitizing agents for cancer chemotherapy

Über Autor(innen)

Chen, Zhe-Sheng (Jason)
Zhe-Sheng Chen opened the St. John's University's first cancer pharmacology laboratory. His research interest is multidrug resistance and its reversal, novel anti-cancer drug development. Chen serves as Editor of "African Journal of Pharmacy and Pharmacology"; Editor-in-Chief of "Journal of Cancer Research Updates" and "Journal of New Developments in Chemistry". He also serves as an Editorial Board member of 25 journals, an Ad Hoc reviewer of 180 journals, and a guest editor of "Current Pharmaceutical Biotechnology", "Cancer" and "Journal of International Medical Research". Chen has over 170 papers published, 6 book chapters, and 5 patents.

Bonavida, Benjamin
Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).